← All countries · Americas
97%
MCV1
2025 · WHO/UNICEF estimate
99%
DTP3
2025 · WHO/UNICEF estimate
88%
IPV complete
2025 · WHO/UNICEF estimate
99%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 99%1990 · Administrative (country-reported) | 99% | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 104.7% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 99%2025 · WHO/UNICEF estimate | 100.1% | B · good | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | 105.4% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 88%2025 · WHO/UNICEF estimate | 101.8% | D · poor | |
| MCV1First dose of measles-containing vaccine | 97%2025 · WHO/UNICEF estimate | 106.2% | B · good | |
| MCV2Second dose of measles-containing vaccine | 82%2025 · WHO/UNICEF estimate | 100.8% | B · good | |
| RCV1First dose of rubella-containing vaccine | 97%2025 · WHO/UNICEF estimate | 106.2% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 99%2025 · WHO/UNICEF estimate | 100.1% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | 74%2025 · WHO/UNICEF estimate | 72.7% | C · weak | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 99%2025 · WHO/UNICEF estimate | 100.1% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | no data |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | —% · Administrative (country-reported) | — | too few points | D · poor |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 2%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 1%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 1%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02019 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (44 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Adults with chronic conditions, older adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y4-Y5 | General/routine | 5yrs |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | M18 |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students, and importer healthcare worker incomplete vaccination status |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students, and importer healthcare worker incomplete vaccination status |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students, and importer healthcare worker incomplete vaccination status |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students, and importer healthcare worker incomplete vaccination status |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students, and importer healthcare worker incomplete vaccination status |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students, and importer healthcare worker incomplete vaccination status |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | infants within the first 24 hours of birth. It could be given until 72 hours. |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y14 | HPV administered to females and males | females and males; aged 9-14 years x1 dose, aged 15-26 years x1 dose. This change was made in 2025. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | 1st contact | Risk group(s) | Residents who did not receive both doses and imported healthcare workers who only have 1 measles dose of vaccine |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | +M1 | Risk group(s) | Residents who did not receive both doses and imported healthcare workers who only have 1 measles dose of vaccine |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | |
| OPVOPV (Oral polio vaccine) | 5 | Y4-Y5 | General/routine | |
| OPVOPV (Oral polio vaccine) | 6 | Y15 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M6 | General/routine | This vaccine was introduced in 2024 as a donation, and in 2025 the country procured the vaccine through the Revolving Fund |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | Risk group(s) | sickle cell disease |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | Risk group(s) | sickle cell disease |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | Risk group(s) | sickle cell disease |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y2 | Risk group(s) | Vaccine given to risk groups >=2 as recommended by the doctor via medical Benefits (eg those with sickle cell disease diabetes ect) |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y25 | Adults | Adults and pregnant women |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Pregnant women | Adults and pregnant women | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y15 | General/routine | |
| VARICELLAVaricella vaccine | 1 | Y3-Y5 | General/routine | |
| VARICELLAVaricella vaccine | 1 | 1st contact | Risk group(s) | This vaccine is given to adults who didn’t receive the vaccine as a child |
| VARICELLAVaricella vaccine | 2 | +W4 | Risk group(s) | This vaccine is given to adults who didn’t receive the vaccine as a child |
| YFYF (Yellow fever) vaccine | 1 | 1st contact | Travellers | Travellers |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.